Form 4: Arcturus Therapeutics Grants CSO & COO Stock Options

Arcturus Therapeutics Holdings Inc. granted its Chief Scientific Officer & COO, Pad Chivukula, 54,000 employee stock options with an exercise price of $6.52.

Summary

• Pad Chivukula, Chief Scientific Officer & COO of Arcturus Therapeutics Holdings Inc. (ARCT), was granted 54,000 employee stock options.
• The options have an exercise price of $6.52 per share.
• The grant date for these options was December 17, 2025.
• The options were granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.
• The shares underlying these options will vest 25% on December 17, 2026, which is the first anniversary of the grant date.
• The remaining shares will vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.
• The options have an expiration date of December 17, 2035.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it reflects a standard executive compensation practice designed to align management's interests with shareholders and incentivize long-term performance. It is not highly positive as it's a routine event rather than a significant new development.

Positives

• The grant of stock options aligns the interests of the Chief Scientific Officer & COO with those of shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice for retaining key executives and motivating them to contribute to the company's growth and success.

Future Outlook

The stock option grant serves as a long-term incentive for the Chief Scientific Officer & COO, aligning their future performance with the company's success over the next decade through the vesting and expiration schedule.

Industry Context

The granting of employee stock options to key executives like the Chief Scientific Officer & COO is a common practice in the biotechnology and pharmaceutical industries. This form of compensation is widely used to attract, retain, and motivate top talent, linking their financial incentives directly to the company's stock performance and long-term value creation, which is crucial in a sector characterized by long development cycles and high R&D investment.

Comparison to Industry Standards

• The use of stock options as a component of executive compensation is a standard practice across the biotechnology and pharmaceutical industries, comparable to compensation structures at companies like Moderna, BioNTech, or Pfizer, which frequently utilize equity grants to incentivize leadership.
• The vesting schedule, with an initial cliff and subsequent monthly increments over several years, is typical for long-term incentive plans designed to ensure executive retention and sustained performance, mirroring common practices seen in similar-stage biotech firms.

Stakeholder Impact

• Shareholders: Potential for future dilution upon exercise of options, but also benefit from incentivized executive performance.
• Employees (specifically Pad Chivukula): Direct financial benefit and long-term incentive tied to company stock performance.

Next Steps

• The options will begin vesting on December 17, 2026, with subsequent monthly vesting increments for 36 months.

Key Dates

Keywords

Arcturus Therapeutics, ARCT, Stock Options, Executive Compensation, Insider Transaction, Form 4, Equity Incentive Plan, Pad Chivukula, Chief Scientific Officer, COO